KindlyMD (NASDAQ:NAKA) CEO David Bailey Acquires 31,500 Shares

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 31,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average price of $5.58 per share, with a total value of $175,770.00. Following the transaction, the chief executive officer owned 3,015,528 shares of the company’s stock, valued at $16,826,646.24. This represents a 1.06% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

KindlyMD Trading Up 3.7%

NAKA opened at $5.60 on Friday. The firm has a market cap of $97.44 million, a P/E ratio of -0.13 and a beta of 17.12. KindlyMD, Inc. has a 12 month low of $4.50 and a 12 month high of $995.60. The stock has a 50-day moving average of $8.21 and a 200 day moving average of $13.07.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The company had revenue of $2.68 million during the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. On average, research analysts forecast that KindlyMD, Inc. will post -16.8 earnings per share for the current fiscal year.

Key KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 104,833 shares at an average price of $4.84, adding to a series of recent open-market purchases and lifting his ownership stake, which may reassure investors about management’s confidence in KindlyMD. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating and $30 price target, with forecasted improvement in later-period earnings, which could help support sentiment around NAKA. Article Title
• Neutral Sentiment: Maxim’s earnings estimates still call for losses in the near term, but they model a shift to profitability in some periods of fiscal 2027, suggesting the turnaround story remains speculative. Article Title
• Negative Sentiment: The company’s latest reported quarter showed a large EPS loss and weak profitability metrics, which continue to highlight execution risk for investors. Article Title

Hedge Funds Weigh In On KindlyMD

Several hedge funds have recently added to or reduced their stakes in the company. Sagespring Wealth Partners LLC purchased a new stake in KindlyMD in the 4th quarter valued at about $28,000. SG Americas Securities LLC purchased a new stake in KindlyMD in the 4th quarter valued at about $61,000. Virtu Financial LLC bought a new stake in shares of KindlyMD during the fourth quarter valued at approximately $151,000. J. Derek Lewis & Associates Inc. bought a new stake in shares of KindlyMD during the fourth quarter valued at approximately $167,000. Finally, Truist Financial Corp bought a new stake in shares of KindlyMD during the fourth quarter valued at approximately $176,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Maxim Group cut their price target on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Weiss Ratings upgraded shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 11th. TD Cowen assumed coverage on shares of KindlyMD in a report on Friday, April 10th. They set a “buy” rating and a $40.00 price target on the stock. B. Riley Financial cut their price target on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $30.00.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.